AIM Vaccine Co., Ltd. Class H (6660) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 2.06M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.18
• Revenue Growth: 6.48%
• EPS Growth: 77.50%
• Country: HK
• Employees: 1,535
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.12
• Shares Outstanding: 507,673,700
• 10 Day Avg. Volume: 2,003,180
• 30 Day Avg. Volume: 2,059,960
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$4.50
• Price Target Upside: 12.22% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: HK$4.50 ▲(12.22% Upside)

AIM Vaccine Co., Ltd. faces significant financial challenges, with declining revenues and persistent net losses being the most impactful factors. Technical analysis provides mixed signals, with short-term weakness indicated. Valuation is unattractive due to a negative P/E ratio and lack of dividend yield.

AIM Vaccine Co., Ltd. Class H Business Overview & Revenue Model

Company Description

AIM Vaccine Co., Ltd. engages in the research and development, manufacturing, and commercialization of vaccine products for human use in the People's Republic of China. The company's product pipeline includes Bivalent Delta-Omicron BA.5 mRNA and Monovalent Omicron BA.5 mRNA, which is in phase III clinical trails for the treatment of COVID-19; EV71-CA16 Bivalent for HFMD; and Valent Pneumococcal Conjugate and Polysaccharide vaccine for pneumococcal disease. It also offers Hexavalent group B Streptococcus Polysaccharide Conjugate Vaccine for Group B strep disease; Diphtheria, Tetanus and Pertussis and Haemophilus In¬uenzae type B, and Diphtheria, Tetanus and Acellular Pertussis, and Absorbed Tetanus for DTP; Haemophilus In¬uenzae Type B for Hib; and freeze-dried human rabies and mRNA human rabies vaccine. In addition, the company develops Human Papillomavirus 2 and 3-valent vaccine; Tetravalent Meningococcal Conjugate vaccine; Tetravalent In¬uenzae vaccine; mRNA Shingles/Herpes Zoster vaccine; mRNA respiratory syncytial virus vaccine; live attenuated parotitis vaccine; and ACYW135 meningococcal polysaccharide vaccine. The company was formerly known as Beijing AIM Biological Vaccine Technology Group Co., Ltd. and changed its name to AIM Vaccine Co., Ltd. in September 2020. AIM Vaccine Co., Ltd. was incorporated in 2011 and is headquartered in Beijing, the People's Republic of China.

How the Company Makes Money

AIM Vaccine Co., Ltd. generates revenue primarily through the sale of its vaccine products to healthcare providers, governments, and international health organizations. The company may also engage in partnerships and collaborations with other pharmaceutical companies or research institutions to co-develop new vaccines, which can result in shared revenues from commercialized products. Additionally, AIM Vaccine Co., Ltd. might receive funding or grants for vaccine research and development, contributing to its financial performance. Key factors influencing its earnings include successful clinical trials, regulatory approvals, and market demand for its vaccines.

AIM Vaccine Co., Ltd. Class H Financial Statement Overview

Summary

AIM Vaccine Co., Ltd. is facing financial challenges with declining revenues, consistent net losses, and cash flow issues. The negative cash flow situation and profitability concerns pose significant risks to financial stability.

Income Statement

AIM Vaccine Co., Ltd. has been experiencing significant revenue volatility with a decline from 2020 to 2023. The gross profit margin has decreased over the years, showing a negative trend in profitability. Additionally, the company has been operating at a net loss, with negative net profit margins and EBIT margins, indicating challenges in managing operating expenses relative to revenue.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio, which suggests a balanced capital structure. However, the return on equity is negative due to sustained net losses. The equity ratio has decreased over time, indicating a shrinking proportion of equity funding.

Cash Flow

The cash flow statement reveals significant issues with free cash flow, which has been consistently negative, reflecting challenges in generating cash from operations. The operating cash flow to net income ratio is concerning, as the company struggles to convert reported earnings into cash. This indicates potential liquidity risks.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.29B	1.19B	1.26B	1.57B	1.64B
Gross Profit	953.51M	-611.21M	1.03B	1.29B	1.35B
EBITDA	-87.37M	-2.05B	-242.03M	-451.71M	629.97M
Net Income	-277.23M	-1.30B	-319.60M	-692.77M	379.29M
Balance Sheet
Total Assets	7.31B	7.26B	8.88B	8.07B	4.69B
Cash, Cash Equivalents and Short-Term Investments	594.87M	736.41M	797.82M	746.74M	1.10B
Total Debt	1.84B	1.80B	1.40B	650.43M	235.04M
Total Liabilities	3.70B	3.37B	3.01B	2.37B	1.27B
Stockholders Equity	3.37B	3.64B	4.96B	4.89B	3.42B
Cash Flow
Free Cash Flow	-139.09M	-467.14M	-966.96M	-1.05B	-416.68M
Operating Cash Flow	99.19M	-165.50M	-110.32M	93.40M	250.33M
Investing Cash Flow	-162.34M	-271.96M	-858.15M	-1.34B	-604.92M
Financing Cash Flow	-26.22M	362.07M	980.37M	788.02M	1.14B

AIM Vaccine Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6660, the sentiment is Negative. The current price of 4.01 is below the 20-day moving average (MA) of 4.56, below the 50-day MA of 4.90, and below the 200-day MA of 4.66, indicating a bearish trend. The MACD of -0.24 indicates Positive momentum. The RSI at 39.14 is Neutral, neither overbought nor oversold. The STOCH value of 20.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6660.

AIM Vaccine Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2696	70 Outperform	HK$40.06B	45.98	27.23%	―	2.57%	18.79%
1877	54 Neutral	HK$42.10B	-26.67	-21.86%	―	44.21%	46.11%
6660	45 Neutral	―	―	-7.87%	―	6.48%	77.50%
2157	44 Neutral	HK$13.85B	-70.52	-58.53%	―	240.05%	-140.09%
2179	41 Neutral	HK$3.63B	-4.86	-106.25%	―	―	-18.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

AIM Vaccine Co., Ltd. Class H Corporate Events

AIM Vaccine Reports Interim Results with Decreased Revenue and Improved Loss Management

AIM Vaccine Co., Ltd. reported its interim results for the six months ended June 30, 2025, showing a 4.2% decrease in revenue and a 12.1% drop in gross profit compared to the same period in 2024. The company also experienced a reduction in its loss attributable to owners of the parent by 5.8%, indicating some improvement in financial management despite the overall loss.

The most recent analyst rating on (HK:6660) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on AIM Vaccine Co., Ltd. Class H stock, see the HK:6660 Stock Forecast page.

AIM Vaccine Co., Ltd. Schedules Board Meeting to Review Interim Results

AIM Vaccine Co., Ltd. has announced a board meeting scheduled for August 27, 2025, to discuss and approve the interim results for the first half of 2025, consider the recommendation of an interim dividend, and address other business matters. This meeting is significant as it will provide insights into the company’s financial performance and potential shareholder returns, impacting its market positioning and stakeholder interests.

AIM Vaccine Announces Key Corporate Secretary Changes

AIM Vaccine Co., Ltd. announced a change in its corporate structure with the resignation of Ms. Lam Wing Chi as Joint Company Secretary, Authorised Representative, and Process Agent, effective June 13, 2025. Ms. Wong Pui Kiu Ingrid has been appointed to these roles. The company expressed gratitude to Ms. Lam for her contributions and welcomed Ms. Wong, who brings over a decade of experience in corporate secretarial and legal advisory services. This change is part of an adjustment in work arrangements and is not due to any disagreements with the board.